Re: Agreement to Amend Conversion Price and Convert – Debentures;Agreement to Amend Conversion Price and Convert – Debentures; Agreement to Amend Debenture Warrants; Receipt of Shares • June 16th, 2017 • Pressure Biosciences Inc • Laboratory analytical instruments
Contract Type FiledJune 16th, 2017 Company IndustryReference is made to that certain Subscription Agreement (the “Subscription Agreement”), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc. (the “Company”) and the holders of the Company’s Senior Secured Convertible Debentures (the “Debenture Holders”); and those certain Senior Secured Convertible Debentures (each a “Debenture” and, together, the “Debentures”) and Common Stock Purchase Warrants issued in connection therewith (the “Debenture Warrants” and, together with the Subscription Agreement and Debentures, the “Debenture Documents”).
Re: Agreement to Convert – Series D Preferred Stock;Agreement to Convert – Series D Preferred Stock • June 16th, 2017 • Pressure Biosciences Inc • Laboratory analytical instruments
Contract Type FiledJune 16th, 2017 Company IndustryReference is made to the 75 shares of Series D Preferred Stock (the “Preferred Stock”) issued by Pressure BioSciences, Inc. (the “Company”) to you in November 2011. The Company expects to undertake a 1 for 30 reverse stock split on Monday, June 5, 2017. Unless the context otherwise requires, all of the numbers reflected herein are represented on a pre-reverse stock split basis.
Re: Agreement to Amend Conversion Price and Convert – Debentures; Agreement to Amend Debenture WarrantsAgreement to Amend Conversion Price and Convert – Debentures; Agreement to Amend Debenture Warrants • June 16th, 2017 • Pressure Biosciences Inc • Laboratory analytical instruments • Massachusetts
Contract Type FiledJune 16th, 2017 Company Industry JurisdictionReference is made to that certain Subscription Agreement (the “Subscription Agreement”), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc. (the “Company”) and the holders of the Company’s Senior Secured Convertible Debentures (the “Debenture Holders”); and those certain Senior Secured Convertible Debentures (each a “Debenture” and, together, the “Debentures”) and Common Stock Purchase Warrants issued in connection therewith (the “Debenture Warrants” and, together with the Subscription Agreement and Debentures, the “Debenture Documents”). You are being sent this letter as you are currently the holder of: (i) a Debenture pursuant to which you are owed principal along with accrued interest (the “Debenture Obligation”); and (ii) Debenture Warrants. The Company expects to undertake a 1 for 30 reverse stock split on Monday, June 5, 2017. Unless the context otherwise requires, all of the numbers reflected herein are represented on a pre-reverse stoc
Re: Agreement to Amend Conversion Price and Convert – Debentures;Pressure Biosciences Inc • June 16th, 2017 • Laboratory analytical instruments • Massachusetts
Company FiledJune 16th, 2017 Industry JurisdictionReference is made to that certain Subscription Agreement (the “Subscription Agreement”), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc. (the “Company”) and the holders of the Company’s Senior Secured Convertible Debentures (the “Debenture Holders”); and those certain Senior Secured Convertible Debentures (each a “Debenture” and, together, the “Debentures”) and Common Stock Purchase Warrants issued in connection therewith (the “Debenture Warrants” and, together with the Subscription Agreement and Debentures, the “Debenture Documents”). The Company expects to undertake a 1 for 30 reverse stock split on Monday, June 5, 2017. Unless the context otherwise requires, all of the numbers reflected herein are represented on a pre-reverse stock split basis.